Extended trial tests promising drug for genetic muscle disease
NCT ID NCT05479981
Summary
This study continued testing an experimental drug called AOC 1001 in adults with myotonic dystrophy type 1, a genetic muscle-wasting disease. It followed 37 participants from a previous trial to check long-term safety and see if the drug continues to work when given every 8 weeks for up to 3 years. The main goal was to monitor side effects while also measuring how the drug affects the underlying genetic problem in muscle tissue.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENETIC DISEASES, INBORN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kansas University Medical Center
Kansas City, Kansas, 66205, United States
-
Ohio State University
Columbus, Ohio, 43221, United States
-
Stanford University
Palo Alto, California, 94304, United States
-
University of California Los Angeles
Los Angeles, California, 90095, United States
-
University of Colorado
Denver, Colorado, 80045, United States
-
University of Florida
Gainesville, Florida, 32608, United States
-
University of Rochester Medical Center
Rochester, New York, 14642, United States
-
Virginia Commonwealth University
Richmond, Virginia, 23298, United States
Conditions
Explore the condition pages connected to this study.